BioAgilytix Labs, LLC, a global CRO, signed a formal, worldwide partnership agreement with Clinical Trial and Consulting Services (CTI), enabling both BioAgilytix and CTI to provide their customers with mutually complementary services as part of an effort to streamline the customer experience and expediting drug development.
 
“Our partnership agreement with CTI further solidifies our already outstanding relationship, as we’ve previously worked together to support their customers and help get therapeutics to patients faster,” said Jim Datin, President and CEO of BioAgilytix. “Not only will their clients now benefit from expedited study lead times due to their access to our teams of scientists and additional laboratory capacity, but we can now also extend many of CTI’s offerings to our customer base.” 
 
“The past two years have demonstrated what can be achieved when members of the medical and research community combine their expertise,” remarked Timothy J. Schroeder, CEO and Chairman of CTI. “Our team and our sponsors are working in cell and gene therapies and other complex programs with the promise to treat – and even cure – devastating diseases. CTI has been on the forefront of personalized medicine for decades, and we look forward to extending BioAgilytix’s complex specialized testing and assay development services to our sponsors to further support life-changing medical advancements.”